Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,417.50INR
3:45pm IST
Change (% chg)

Rs-39.15 (-1.59%)
Prev Close
Rs2,456.65
Open
Rs2,465.00
Day's High
Rs2,477.00
Day's Low
Rs2,406.70
Volume
66,410
Avg. Vol
58,863
52-wk High
Rs3,394.95
52-wk Low
Rs1,901.65

Chart for

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.17
Market Cap(Mil.): Rs407,690.31
Shares Outstanding(Mil.): 165.88
Dividend: 20.00
Yield (%): 0.81

Financials

  Industry Sector
P/E (TTM): -- 30.87 15.95
EPS (TTM): -- -- --
ROI: -- 14.31 15.19
ROE: -- 15.61 13.87

BRIEF-Dr.Reddy's Labs says FDA completes ‍audit of co's Telangana facilities with no observations​

* FDA completes ‍audit of co's Telangana custom pharmaceutical services facility, technology development centre with no observations​ Source text: http://bit.ly/2hhsmbf Further company coverage:

21 Sep 2017

BRIEF-Dr.Reddy's Laboratories gets EIR from US FDA for Formulation Srikakulam plant

* Says received an establishment inspection report (EIR) from US FDA for formulation Srikakulam plant Source text for Eikon: Further company coverage:

21 Sep 2017

Indivior files lawsuits against Suboxone generic rivals

Indivior's U.S. subsidiary has filed lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of the drugmaker's revenue.

15 Sep 2017

UPDATE 1-Indivior files lawsuits against Suboxone generic rivals

Sept 15 Indivior's U.S. subsidiary has filed lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of the drugmaker's revenue.

15 Sep 2017

BRIEF-Dr.Reddy's Labs' Aurigene, Curis to start mid-stage study of CA-170

* Says Aurigene Discovery Technologies, Curis plan to initiate phase 2 trial of CA-170 in India‍​

12 Sep 2017

Dr Reddy's says German regulator makes six observations on unit

Dr. Reddy's Laboratories said on Friday a German regulator has made six major observations about its Duvvada drug making facility in the southern Indian state of Andhra Pradesh, sending shares down as much as 7.1 percent.

08 Sep 2017

India's Dr Reddy's says German regulator makes 6 observations on unit

Sept 8 Dr. Reddy's Laboratories said on Friday a German regulator has made six major observations about its Duvvada drug making facility in the southern Indian state of Andhra Pradesh, sending shares down as much as 7.1 percent.

08 Sep 2017

BRIEF-Dr.Reddy's Laboratories says Regulatory Authority of Germany concludes audit of facility

* Regulatory Authority of Germany concluded audit of formulations manufacturing facility in Vishakapatnam

08 Sep 2017

BRIEF-Dr. Reddy's Laboratories announces launch of two drugs in U.S. market

* Says announces launch of bupropion hydrochloride extended-release tablets, USP (XL) in U.S. Market

06 Sep 2017

London-listed drugmaker Indivior shares crash after U.S. patent blow

Shares in London-listed Indivior plunged 40 percent after the drugmaker said a U.S. court ruling could clear the way for a generic rival to its treatment for opioid addiction that generates 80 percent of its revenues.

01 Sep 2017

Earnings vs. Estimates